| Literature DB >> 35168683 |
Martine Sabbe1,2, Javier Sawchik3, Mégane Gräfe4, Françoise Wuillaume3, Sara De Bruyn5, Pierre Van Antwerpen6, Guido Van Hal7, Martin Desseilles8, Jamila Hamdani3, Hugues Malonne3,4,9.
Abstract
BACKGROUND: Misuse of prescription stimulants (PS) has been reported among students to enhance academic performance in Flanders (Belgium). However, PS misuse among students in the French-speaking community is unknown. The main purpose of the study was to estimate the prevalence of medical use and misuse of PS by university students in the French-speaking community (Belgium), and to investigate the reasons and sources associated with PS misuse.Entities:
Keywords: Belgium; Drug misuse; Methylphenidate; Misuse of prescription drugs; Stimulants; Survey; University
Year: 2022 PMID: 35168683 PMCID: PMC8848864 DOI: 10.1186/s13690-022-00816-3
Source DB: PubMed Journal: Arch Public Health ISSN: 0778-7367
Socio-demographic characteristics overall and by use of prescription stimulants, survey in French-speaking universities, Belgium, 2018
| Characteristic | Users | No users | Overall |
|---|---|---|---|
Age (years) n Mean (SD) Median (Q1-Q3) | 729 22.4 (2.9) 22 (20-24) | 10 363 21.1 (2.8) 21 (19-23) | 11,092 21.2 (2.8) 21 (19-23) |
Gender n Female Male Other | 732 360 (49.2, 45.6-52.8) 363 (49.6, 46.0-52.2) 9 (1.2, 0.6-2.3) | 10 401 6 932 (66.6, 65.7-67.6) 3 420 (32.9, 32.0-33.8) 49 (0.5, 0.3-0.6) | 11 133 7 292 (65.5, 64.6-66.3)) 3 783 (34.0, 33.1-34.9) 58 (0.5, 0.4-0.7) |
School year n Bachelor (1st year) Bachelor (other) Master | 715 160 (22.4, 19.4-25.6) 237 (33.1, 29.7-36.7) 318 (44.5, 40.8-48.2) | 10 199 3 319 (32.5, 31.6-33.5) 3 139 (30.8, 29.9-31.7) 3 741 (36.7, 35.7-37.6) | 10 914 3 479 (31.9, 31.0-32.8) 3 376 (30.9, 30.1-31.8) 4 059 (37.2, 36.3-38.1) |
Working status No job Vacation job Job < 20 h/week Job ≥ 20 h/week | 716 286 (39.9, 36.3-43.6) 144 (20.1, 17.2-23.2) 191 (26.7, 23.5-30.1) 95 (13.3, 10.9-16.0) | 10 161 4 630 (45.6, 44.6-46.5) 2 718 (26.7, 25.9-27.6) 2 152 (21.2, 20.4-22.0) 661 (6.5, 6.0-7.0) | 10 877 4 916 (45.2, 44.3-46.1) 2 862 (26.3, 25.5-27.2) 2 343 (21.5, 20.8-22.3) 756 (7.0, 6.5-7.4) |
Housing status n With parents/family Flat sharing Alone Other | 713 331 (46.4, 42.8-50.1) 214 (30.0, 26.7-33.6) 150 (21.0, 18.1-24.2) 18 (2.5, 1.5-4.0) | 10 132 5 529 (51.6, 50.6-52.6) 3 007 (29.7, 28.8-60.6) 1 619 (16.0, 15.3-16.7) 277 (2.7, 2.4-3.1) | 10 845 5 560 (51.3, 50.3-52.2) 3 221 (29.7, 28.8-30.6) 1 769 (16.3, 15.6-17.0) 295 (2.7, 2.4-3.0) |
Descriptive statistics for age, n (%, 95%CI) for categorical variables
Reasons for using prescription stimulants for purposes other than treatment, survey in French-speaking universities, Belgium, 2018
| Reasons | n (%) | 95% Clopper-Pearson CI |
|---|---|---|
| To concentrate when studying | 414 (76.1) | 72.3-79.7 |
| To stay awake and study longer | 276 (50.7) | 46.5-55.0 |
| To improve intellectual performance | 256 (47.1) | 42.9-51.3 |
| To better memorize the courses | 240 (44.1) | 39.9-48.4 |
| To try | 116 (21.3) | 18.0-25.0 |
| To party | 42 (7.7) | 5.6-10.3 |
| To disconnect from reality | 27 (5.0) | 3.3-7.1 |
| To lose weight | 27 (5.0) | 3.3-7.1 |
| To improve sport performance | 18 (3.3) | 2.0-5.2 |
| To do like others | 8 (1.5) | 0.6-2.9 |
| Other | 36 (6.6) | 4.7-9.0 |
Only 25 medical users reported reasons other than treatment for use of prescription stimulants
Sources for obtaining prescription stimulants for medical use and misuse, survey in French-speaking universities, Belgium, 2018
| Source | Medical users ( | Misusers ( | |||
|---|---|---|---|---|---|
| Peers (student community) | 6 (2.3) | 0.9-5.0 | 199 (41.5) | 37.0-45.9 | <0.0001 |
| General practitioner | 99 (38.1) | 32.1-44.0 | 113 (23.5) | 19.8-27.6 | <0.0001 |
| Friends / acquaintances | 7 (2.7) | 1.1-5.5 | 75 (15.6) | 12.5-19.2 | <0.0001 |
| Sibling / other family member | 6 (2.3) | 0.9-5.0 | 57 (11.9) | 9.1-15.1 | <0.0001 |
| Parents | 9 (3.5) | 1.6-6.5 | 50 (10.4) | 7.8-13.5 | 0.0009 |
| Internet | 3 (1.2) | 0.2-3.3 | 45 (9.4) | 6.9-12.3 | <0.0001 |
| Neurologist / psychiatrist | 220 (84.6) | 79.6-88.8 | 39 (8.1) | 5.8-10.9 | <0.0001 |
| Theft (drug/prescription) | 3 (1.2) | 0.2-3.3 | 7 (1.5) | 0.6-3.0 | 1.00b |
| Other | 6 (2.3) | 0.9-5.0 | 19 (4.0) | 2.4-6.1 | 0.2 |
95%CI: Clopper-Pearson confidence interval
a Chi-square test, b Fisher’s exact test (25% of the cells have expected counts less than 5)
Perceived negative effects associated with the use of prescription stimulants, survey in French-speaking universities, Belgium, 2018
| Negative effects | Medical users ( | Misusers ( | |||
|---|---|---|---|---|---|
| Sleep disorders | 103 (57.2) | 49.6-64.6 | 142 (58.0) | 51.5-64.2 | 0.9 |
| Palpitations | 70 (38.9) | 31.7-46.4 | 131 (53.8) | 47.0-59.8 | 0.003 |
| Emotional instability | 84 (46.7) | 39.2-54.2 | 105 (42.9) | 36.6-49.3 | 0.4 |
| Agitation | 47 (26.1) | 19.9-33.2 | 93 (38.0) | 31.9-44.4 | 0.01 |
| Aggressiveness | 54 (30.0) | 23.4-37.3 | 71 (29.0) | 23.4-35.1 | 0.8 |
| Headaches | 33 (18.3) | 13.0-24.8 | 73 (29.8) | 24.1-35.9 | 0.007 |
| Depression | 62 (34.4) | 27.5-41.9 | 57 (23.3) | 18.1-29.1 | 0.01 |
| Nausea | 47 (26.1) | 19.9-33.2 | 40 (16.3) | 11.9-21.6 | 0.01 |
| Anorexia | 51 (28.3) | 21.8-35.5 | 39 (15.9) | 11.6-21.1 | 0.002 |
| Suicidal thoughts | 26 (14.4) | 9.7-20.4 | 27 (11.0) | 7.4-15.6 | 0.3 |
| Hallucinations | 9 (5.0) | 2.3-9.3 | 12 (4.9) | 2.6-8.4 | >0.9 |
| Other | 33 (18.3) | 13.0-24.8 | 28 (11.4) | 7.7-16.1 | 0.04 |
a95%CI: Clopper-Pearson confidence interval
bChi-square test
Perceived positive effects associated with the use of prescription stimulants, survey in French-speaking universities, Belgium, 2018
| Positive effects | Medical users ( | Misusers ( | |||
|---|---|---|---|---|---|
| Improved concentration | 231 (95.9) | 92.5-98.0 | 364 (89.0) | 85.6-91.9 | 0.002 |
| Stay awake / study longer | 82 (34.0) | 28.1-40.4 | 235 (57.5) | 52.5-62.3 | <0.0001 |
| Motivation to study | 115 (47.7) | 41.3-54.2 | 205 (50.1) | 45.3-55.0 | 0.6 |
| More energy | 92 (38.2) | 32.0-44.6 | 204 (49.9) | 45.0-54.7 | 0.004 |
| Improved results | 133 (55.2) | 48.7-61.6 | 170 (41.6) | 36.7-46.5 | 0.0008 |
| Sport performance | 16 (6.6) | 3.8-10.§ | 14 (3.4) | 1.9-5.7 | 0.06 |
| Other | 44 (17.4) | 12.3-22.6 | 46 (10.6) | 7.8-13.8 | 0.01 |
a95%CI: Clopper-Pearson confidence interval
bChi-square test
Association between use of stimulants, sociodemographics and other substances, survey in French-speaking universities, Belgium, 2018
| Covariate | Medical users ( | Misusers ( | ||
|---|---|---|---|---|
| Age (years) | 1.11 | 1.06-1.16c | 1.19 | 1.15-1.24c |
| Gendera | 1.83 | 1.43-2.42c | 1.87 | 1.52-2.32c |
| Nicotineb | 1.48 | 1.04-2.07c | 2.29 | 1.78-2.92c |
| Energy drinksb | 1.11 | 0.81-1.50 | 2.22 | 1.78-2.76c |
| Hypnotics, Sedativesb | 2.21 | 1.36-3.44c | 2.04 | 1.42-2.89c |
| Corticosteroidsb | 4.48 | 2.25-8.22c | 2.44 | 1.26-4.47c |
| Cannabisb | 1.48 | 0.97-2.21 | 1.90 | 1.43-2.51c |
| Amphetaminesb | 3.35 | 0.83-11.08 | 2.13 | 0.84-5.39c |
| Ecstasyb | 4.12 | 0.75-17.99 | 1.93 | 0.70-5.18 |
| Cocaineb | 0.28 | 0.03-1.55 | 4.51 | 2.08-9.51c |
Odds Ratio (OR) and 95% Profile-likelihood confidence interval obtained from a multinomial logistic model
amale vs. female, b>1month vs. ≤ 1 month, cOR statistical significant at the 5% level